

# Augmenting tendon and ligament repair with platelet-rich plasma (PRP)

Ting Yuan<sup>1,2</sup>  
Chang-Qing Zhang<sup>2</sup>  
James H-C. Wang<sup>1</sup>

<sup>1</sup> MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, School of Medicine, Pittsburgh, USA

<sup>2</sup> Department of Orthopaedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai, Jiatong University, Shanghai, China

## Corresponding author:

James H-C. Wang, PhD  
Laboratory  
Department of Orthopaedic Surgery  
University of Pittsburgh  
School of Medicine  
210 Lothrop Street, BST, E1640  
Pittsburgh, PA 15213, USA  
E-mail: wanghc@pitt.edu

## Summary

**Tendon and ligament injuries (TLI) commonly occur in athletes and non-athletes alike, and remarkably debilitate patients' athletic and personal abilities. Current clinical treatments, such as reconstruction surgeries, do not adequately heal these injuries and often result in the formation of scar tissue that is prone to re-injury. Platelet-rich plasma (PRP) is a widely used alternative option that is also safe because of its autologous nature. PRP contains a number of growth factors that are responsible for its potential to heal TLIs effectively. In this review, we provide a comprehensive report on PRP. While basic science studies in general indicate the potential of PRP to treat TLIs effectively, a review of existing literature on the clinical use of PRP for the treatment of TLIs indicates a lack of consensus due to varied treatment outcomes. This suggests that current PRP treatment protocols for TLIs may not be optimal, and that not all TLIs may be effectively treated with PRP. Certainly, additional basic science studies are needed to develop optimal treatment protocols and determine those TLI conditions that can be treated effectively.**

*KEY WORDS: tendon and ligament injury, tendinopathy, PRP, growth factors.*

## Introduction

Tendon and ligament injuries (TLIs) are among the most common health problems affecting the adult population<sup>1</sup>. About 16.4 million tendon and ligament injuries occur in the United States every year<sup>2</sup> and the incident rate of TLIs is expected to rise drastically as the population ages and remains active.

Once injured, tendons and ligaments do not completely re-gain the biological and biomechanical properties of normal tendons and ligaments due to the formation of scars and adhesions<sup>3,4</sup>. This abnormality in structure/arrangement after healing often makes the tissue susceptible to re-injury<sup>5</sup>. Another issue is the relatively slow rate of tendon/ligament healing after TLIs, which is most likely due to their poor vascularization compared to other connective tissues<sup>6</sup>. These problems associated with the healing of TLIs pose a considerable challenge for clinicians.

In recent years, a promising new treatment option using platelet-rich plasma (PRP) has been widely used in clinics to treat TLIs<sup>7-13</sup>. PRP is the plasma fraction of autologous blood containing high concentration of platelets and growth factors. After activation, PRP delivers various types of growth factors to injury sites, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF- $\beta$ ), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), fibroblastic growth factor (FGF), and hepatocyte growth factor (HGF)<sup>14-17</sup>. Because most of these factors are involved in the repair of tendon and ligament injuries<sup>15,18</sup> high concentrations of these growth factors are considered to accelerate TLI healing<sup>19,20</sup>. During healing, tendons are responsive to circulation-derived or locally produced growth factors, most of which are found within PRP<sup>17,21-25</sup>. Therefore in recent years PRP application has been used as a strategy to enhance the healing of injured tendons.

Because PRP is prepared from autologous blood, it is inherently safe. Activated PRP acts not only as a native carrier of multiple growth factors, which stimulate cell proliferation, but also as a 3-dimensional bioactive scaffold (fibrin gel) with a mesh-like microstructure, which enhances cell migration and incorporation<sup>26</sup>. Another presumed advantage of PRP is that unlike individually-isolated growth factors that are used in arbitrary concentrations during treatments, multiple growth factors in PRP are present in physiological proportions, with a natural balance of proliferative and inhibitory agents<sup>27</sup>. Additionally, PRP preparation via centrifugation has been greatly simplified in

recent years, thanks to the development of commercial PRP preparation devices. These technological advances have allowed PRP treatments to move from operating rooms to outpatient offices, and PRP can now be produced easily and safely in 15-30 minutes<sup>14</sup>. As a result, PRP therapy is now widely applied in orthopaedics and sport medicine to treat TLIs.

Many *in vitro* and *in vivo* studies on mammalian models have shown that PRP treatments heal TLIs by enhancing collagen gene expression, stimulating angiogenesis, increasing cell migration, differentiation, and proliferation, and increasing extracellular matrix production<sup>15,28,29</sup>. Clinically, only a few studies have shown promising results on the application of PRP to treat TLIs<sup>7,10-12,30-32</sup>.

To better understand how PRP may influence the healing of injured tendons and ligaments, we analyzed the existing evidence on the efficacies and mechanisms of PRP's action gained through basic science studies and clinical trials. In this review, the characterization of PRP is presented first. Next, experiments from basic science studies and the mechanisms by which PRP repairs TLIs at the molecular, cellular, and organismal (animal model) levels are discussed. Then we present clinical applications of PRP in tendon and ligament healing including its uses in the treatment of acute and chronic tendon injuries. Finally, based on these studies, we comment on the existing basic and clinical findings, and suggest future directions for basic research and clinical applications of PRP for the treatment of TLIs.

## The PRP terminology

PRP has been described in the literature under different names and abbreviations. Some authors define PRP as only platelets, whereas others note that PRP also contains increased concentrations of leukocytes, fibrin, and some bioactive proteins<sup>31</sup>. Based on these descriptions, PRP was classified into pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (L-PRP), and leukocyte- and platelet-rich fibrin (L-PRF)<sup>33,34</sup>. Still, some authors regard autology and growth factors as unique advantages of PRP and prefer the terms autologous platelet concentrate (APC), or plasma-rich growth factors (PRGFs)<sup>27,35</sup>. Based on whether PRP is activated to form gel or not, PRP was also divided into platelet plasma (non-activated platelet) and platelet gel or PRP clot (activated platelet)<sup>17</sup>. Various other terms are also used in the literature, including autologous growth factors (AGF)<sup>36</sup>, platelet-leukocyte gel (PLG)<sup>37</sup>, autologous platelet gel (APG)<sup>38</sup>, platelet-rich gel (PRG)<sup>39</sup>, and platelet-rich fibrin (PRF)<sup>32</sup>. In view of the general confusion over PRP terminology, it should be emphasized that different preparations of PRP may have the same name despite having different properties, while similar preparations of PRP might have different names despite having the same properties.

## Platelet concentration in PRP

By definition, PRP contains a higher concentration of platelets than baseline levels in whole blood and is the most important feature of PRP. Although it would seem intuitive that a higher platelet count would yield more growth factors and better clinical outcomes, this is still under debate. A study on the efficacy of PRP treatments with different platelet concentrations (1.34x vs 1.80x) used to repair patellar tendons in rats showed no significant difference between the 1.34x group and the control group treated with whole blood<sup>40</sup>. Only the group treated with higher platelet concentration (1.80x) showed significantly higher ultimate tensile load and energy absorbed to failure. Kajikawa<sup>29</sup> treated rat patellar tendons using PRP with platelet concentration 8.8 times the number of platelets in whole blood ( $523.8 \times 10^4/\mu\text{l}$  in PRP, and  $59.3 \times 10^4/\mu\text{l}$  in the whole blood), and showed that even at such high platelets concentrations, PRP could increase cell proliferation and enhance cell migration significantly when compared to the control group.

However, some authors recommend not using an overly-high platelet concentration for tissue healing. A platelet concentration about 4-5 times higher than baseline concentration was sufficient to enhance bone and soft tissue healing<sup>41</sup>, while higher concentrations did not further enhance healing<sup>42</sup>. It was reported that a lower concentration of 2.5 times the baseline levels was optimal to induce cell proliferation of osteoblasts and fibroblasts, with higher concentrations (3.5x, and 4.2-5.5x) resulting in reduced numbers of osteoblasts and fibroblasts<sup>43</sup>. More research is therefore needed to determine the optimal biological effects of PRP with different platelet concentrations in different conditions.

## The components of PRP

Both the cellular and molecular components of PRP are well described in many reviews. In this review, we present only a concise summary of these components. More detailed information on individual or combined components is provided by Molloy<sup>23</sup>, Aïssou<sup>16,44</sup>, and Taylor<sup>19</sup>, among others.

### Cellular components

The main cellular components of PRP are platelets, and white blood cells (leukocytes). Platelets, which are the critical components of PRP, are not only a source of growth factors and chemokines, but also express chemokine receptors that regulate inflammatory response<sup>45</sup>.

In addition to platelets, PRP preparations often contain white blood cells that cause biological effects that differ from PRP preparations without white blood cells. To differentiate between the two PRP prepara-

tions, some authors use terms such as leukocyte- and platelet-rich plasma (L-PRP) and pure platelet-rich plasma (P-PRP)<sup>34,46</sup>. Most current commercial PRP systems, including SmartPreP (Harvest, USA)<sup>47</sup>, PCCS (3I, USA)<sup>48</sup>, GPS (Biomet Biologics, USA)<sup>49</sup>, and Curasan (Kleinostheim, Germany), produce L-PRP<sup>48</sup>.

The leukocytes in PRP include neutrophils, monocytes, macrophages, and lymphocytes, which contribute to bacterial killing<sup>39,50</sup>. Leukocytes also impart other beneficial effects on tendon healing: when ACL fibroblasts were cultured in the presence of P-PRP and peripheral blood mononuclear cells (PBMC, consisting of monocytes, macrophages, and lymphocytes, but not neutrophils), significant increases in type I and type III procollagen gene expression, collagen protein production, and cell proliferation were observed, in comparison to the group cultured with only P-PRP. This was accompanied by increased expression of IL-6, which is known to stimulate collagen synthesis in tendons<sup>51,52</sup>. It should be noted that the anabolic effects of PBMCs on ACL fibroblasts were observed only in the presence of platelets, and such effects were not observed when ACL fibroblasts were exposed to PBMCs with PPP or saline. Therefore, platelets may be essential for PBMCs to exert an anabolic effect on fibroblasts and may execute this effect by stimulating PBMCs to secrete IL-6<sup>51</sup> and release their multiple growth factors. On the other hand, leukocytes in PRP also release inflammatory cytokines, including IL-1 $\beta$ , TNF- $\alpha$ , MMP-8, and oxygen-free radicals, that cause catabolic effects on cells and damaged tissues<sup>53</sup>. Whether the beneficial effects of leukocytes in PRP surpass the detrimental effects still remains a matter of debate, and additional studies are needed to prove or disprove this argument. Regardless, it is suggested that in clinical applications PRP without leukocytes should be used for tendon and ligament repair because of the potential complications from inflammatory cytokines and toxic molecules released by leukocytes<sup>54</sup>.

It should be noted that when activated, PRP is like a fibrin matrix, which incorporates platelets and facilitates platelet-derived growth factors release at the site of injury to improve tendon repair. Fibrin also contributes to the formation of a flexible network supporting cytokine enmeshment and cellular migration<sup>55</sup>. However, higher concentrations of fibrin is reported to decrease fibroblast proliferation and biosynthetic activity<sup>56</sup>.

### **Molecular components**

#### **Growth factors**

It is beyond doubt that growth factors released by activated platelets in PRP play a crucial role in enhancing TLI healing. Many studies have elucidated the functions of these growth factors<sup>1,17,23,44</sup>, including PDGF, TGF- $\beta$ , VEGF, IGF, HGF, EGF, and bFGF. All these growth factors are also markedly up-regulated

following TLIs and are active during multiple phases of the healing process<sup>23,57,58</sup>.

PDGF is released by the degranulating platelets at the time of injury, and peaks shortly after tendon damage<sup>59</sup>. It plays multiple roles in the TLI healing process as a whole, including the inflammatory, proliferation, and remodeling phases. For example, it regulates chemotaxis, angiogenesis, mitogenesis of fibroblasts, as well as macrophage activation; it also stimulates the production of other growth factors, such as IGF-I, TGF- $\beta$ 1, and VEGF<sup>60,61</sup>. In fact, application of PDGF alone has been demonstrated to improve the strength and stiffness of treated ligaments<sup>62</sup>.

TGF- $\beta$  exists in platelets, macrophages, fibroblasts, and other cell types, with platelets being the major producers of TGF- $\beta$ <sup>25,59</sup>. Similar to PDGF, TGF- $\beta$  is active throughout the whole process of tendon healing<sup>23</sup> and exerts various effects, such as fibroblast stimulation, macrophage recruitment, cell proliferation, and collagen production<sup>63</sup>. Although TGF- $\beta$  enhances tendon healing, it also contributes to the formation of uncontrolled excessive scarring<sup>25</sup>. Additional studies are needed to find the optimal levels of TGF- $\beta$  to form normal tendon tissue, but not result in disorganized scar formation.

VEGF is a powerful stimulator of angiogenesis, and is produced in high levels only at the end of the inflammatory phase<sup>64</sup>. A number of studies have shown that VEGF improves revascularization and the biomechanical properties of autografts and allografts after ACL reconstruction<sup>65-68</sup>. Despite VEGF's widely-reported positive effects on tendon and ligament healing, it also causes some adverse effects. VEGF application has been reported to temporarily decrease the strength of grafted tendons after ACL reconstruction<sup>69</sup>. One presumed reason for this is that the newly formed vessels and infiltrated cells induced by VEGF act as "flaws," which decreases the mechanical properties of ACL grafts. Another plausible reason could be that enhanced production of matrix metalloproteinase (MMP) induced by VEGF directly "digests" the matrix in the graft<sup>68</sup>.

IGF-I is an important mediator involved in all phases of wound healing. It stimulates fibroblast proliferation and migration, collagen gene expression and protein synthesis, as well as extracellular matrix synthesis both *in vitro* and *in vivo* on animal models<sup>70,71</sup>. In humans, local injection of IGF-I into the patellar tendon increases collagen synthesis<sup>72</sup>. Moreover, application of IGF-I to tendons improves the ultimate load<sup>24,73</sup>.

EGF is important for the migration and proliferation of tendon/ligament cells<sup>70,74</sup>, and collagen synthesis<sup>75</sup>. However, EGF also imparts negative effects on ligament cells and collagen production<sup>76</sup>. For example, the addition of EGF to ACL fibroblast cultures slightly decreases collagen production and the ratio of collagen type I to type III<sup>70</sup>. Therefore, the beneficial effects of EGF on TLI healing need further investigation.

bFGF, which is present in blood at very low concentrations<sup>77</sup>, stimulates angiogenesis and regulates cell

proliferation and migration<sup>78,79</sup>. These stimulatory effects of bFGF are concentration-dependent: 2 ng/ml and 10 ng/ml lead to significantly better wound closure than the control, but a higher concentration of 50 ng/ml impairs wound closure<sup>78</sup>. It is presumed that bFGF at a higher concentration stimulates other low-affinity receptors and thereby impairs wound closure<sup>80</sup>.

In addition to being an anti-inflammatory molecule<sup>81</sup>, HGF is an angiogenic mediator, derived from both platelets and plasma<sup>17,82</sup>. It induces VEGF expression during inflammation and contributes to angiogenesis by participating in the proliferation and remodeling phases of tissue healing<sup>83</sup>. Local administration of HGF accelerates healing after medial collateral ligament (MCL) injury<sup>84,85</sup>. HGF also promotes tissue regeneration and reduces scar formation because of its antifibrotic property<sup>86</sup>. However, it is still a considerable challenge to promote recovery of injured tendons and ligaments without causing excessive scar formation.

It should be emphasized that while PRP contains all the growth factors mentioned above, its "collective" function in TLI healing is not the "sum" of the functions of individual growth factors.

#### *Other factors*

Besides the aforementioned growth factors, PRP contains a wide variety of less-emphasized molecular components such as PF-4, osteocalcin, osteonectin, fibrinogen, vitronectin, fibronectin, and thrombospondin-1, which are released from  $\alpha$ -granules after platelet activation. These proteins also induce cellular proliferation, extracellular matrix formation, and collagen synthesis<sup>44</sup>. In addition, adenosine, serotonin, histamine, and calcium released from dense granules also play a role in tissue healing<sup>31</sup>.

Furthermore, autologous thrombin in PRP has gradually attracted researchers' attention, as it is safer than bovine thrombin, which is frequently used to induce PRP gel formation in patients with tendon/ligament injury<sup>87</sup>. Bovine thrombin has been shown to induce antibodies against factor V, factor XI, and thrombin that can result in potentially life-threatening conditions<sup>88</sup>. Apart from converting fibrinogen into fibrin during clot formation, thrombin has been shown to directly stimulate mitogenesis, stimulate cells to release elaborate growth factors, and increase the mechanical strength of healed tendons<sup>89,90</sup>.

In addition, PRP also contains multiple antimicrobial peptides<sup>91</sup> that contribute to the antimicrobial effect of PRP<sup>92</sup>. The antibacterial functions of autologous PRP have been a hot research topic in recent years<sup>93-95</sup>.

### **Basic science studies on PRP**

The majority of basic science studies using *in vitro* and *in vivo* models clearly demonstrate PRP's ability to accelerate the healing process of TLIs<sup>15,29,40,96-99</sup>.

These findings shed new insights into the cellular and molecular mechanisms by which PRP enhances the healing of injured tendons and ligaments. It is known that repair of injured tendons and ligaments requires progenitor/stem cell recruitment and differentiation, fibroblast proliferation, collagen production, angiogenesis, and mechanical loading, which are discussed below.

#### ***Fibroblasts and collagen***

The major proportion of cells in tendons and ligaments are fibroblasts, and the major extracellular component is collagen. A number of basic studies have demonstrated that PRP can increase both the number of cells and the cellular component by enhancing fibroblast proliferation and collagen production, and thus strengthen healed tendons and ligaments<sup>15,17,100,101</sup>. Application of the PRP releasate to human tendon cells in culture stimulated cell proliferation<sup>17</sup> and when healthy tendon and ligament tissue explants were cultured in medium containing PRP, there was an improvement in both COL1A1 expression and the ratio of COL1A1:COL3A1<sup>101</sup>. In addition, PRP injection into the Achilles tendons of rats improved not only collagen production in tendons, but also their tensile strength<sup>102</sup>.

#### ***Tendon stem/progenitor cells***

Besides fibroblasts, tendons contain another important cell population: tendon stem/progenitor cells (TSC)<sup>15,103,104</sup>. TSCs play a vital role in tendon maintenance and repair due to their ability to self-renew and differentiate into tenocytes<sup>2</sup>. PRP releasate induces differentiation of TSCs into tenocytes, which proliferate quickly and produce abundant collagen<sup>15</sup>.

#### ***Circulation-derived stem cells***

Apart from its effects on local TSCs and fibroblasts, PRP also has a strong potential to recruit circulation-derived stem cells. Local injections of PRP into rat patellar tendons increases the migration of circulation-derived stem cells, which are more proliferative and produce more collagen type I and type III than the control group<sup>29</sup>.

#### ***Angiogenesis***

The angiogenic effect of PRP is attributed to the presence of endothelial growth factor (EGF) in the endothelial cells, which are primarily responsible for new blood vessel growth, because neutralization of EGF in PRP causes a significant decrease in endothelial cells proliferation<sup>105</sup>. PRP injections into a mouse leg ischemia model for angiogenic evaluation increased the number of newly-formed blood vessels

and the blood reperfusion levels of ischemic tissues when compared to the control groups<sup>106</sup>.

### **Mechanical loading**

Mechanical loads greatly influence tenocyte differentiation and proliferation. Many studies have shown that mechanical loading enhances fibroblast proliferation, collagen synthesis, and collagen realignment, leading to increased tendon strength and accelerated tendon healing<sup>2,29,107</sup>. Appropriate mechanical loading is beneficial for the tendons because it induces differentiation of TSCs into tenocytes<sup>15</sup>. However, excessive mechanical loading induces differentiation of TSCs into non-tenocyte lineages such as adipocytes, chondrocytes, and osteocytes, in addition to tenocytes<sup>15</sup>. One likely reason for this aberrant differentiation, which could lead to tendinopathy, is an increase in PGE<sub>2</sub> levels induced by mechanical overloading. It has been shown that PGE<sub>2</sub> decreases TSCs proliferation and collagen production and induces both adipogenesis and osteogenesis *in vitro*<sup>15</sup>.

### **Age-dependency**

The effects of PRP are also age-dependent. Application of PRP obtained from immature/young patients significantly increased both cell migration and proliferation of human ACL fibroblasts than PRP from mature individuals<sup>56</sup>. This is likely due to the higher quantities of healing-capable stem cells known to exist in immature or young humans than older ones, with levels ranging from 1/100,000 in a teenager, 1/250,000 in a 35 year old, 1/400,000 in a 50 year old, and 1/1,200,000 in a 80 year old<sup>59,108</sup>. Therefore, it may be postulated that young patients would respond more favorably to treatment with PRP.

## **Clinical applications of PRP**

Clinical applications of PRP for TLIs mainly focus on Achilles tendon injury, rotator cuff repair, patellar and elbow tendinosis, and anterior cruciate ligament (ACL) reconstruction. Although standardized treatment guidelines for the use of PRP are limited [Platelet Rich Plasma (PRP) Guidelines, 2010, 2011 by the International Cellular Medical Society] and large-sample, high-quality scientific studies are still not available to support its use, PRP treatment is increasingly utilized in sport medicine. More than 86,000 athletes with acute and chronic tendon, ligament, and muscle injuries are reported to be treated with PRP annually in the United States and some European countries<sup>77</sup>.

Overall, PRP treatment has an excellent safety record in clinical applications. The adverse effects reported are minimal with only one patient having a synovial reaction around the ACL<sup>109</sup> and another patient reporting severe pain that lasted for 3 weeks<sup>9</sup>.

However, these are common reactions, and the rate of pain after PRP injection was not higher than the rate in control group<sup>110</sup>.

### **Treatment of injured tendons with PRP**

#### **Tendons with acute injury**

Acute tendon injury has become a common problem in modern society, with spontaneous Achilles tendon ruptures occurring frequently among athletes<sup>111</sup> and active individuals. In general, surgical treatments have offered patients fairly good functional results, but like any other surgery, complications also occur during tendon surgery, including long recovery periods, high incidences of re-rupture, and wound infection<sup>32,112</sup>.

In an effort to treat athletes with complete ruptures of the Achilles tendon, activated PRP was injected into the tendons during a surgical procedure<sup>32</sup>. Six athletes treated with PRP took significantly less time to improve their range of motion in the ankle, resume gentle running, and begin training activities when compared to control athletes who had conventional surgical treatment. This was the first study to report on the efficacy of PRP in the treatment of injured tendons, but it is retrospective and has a limited sample size (a total of 12 athletes). Another study using PRP to treat acute tendon injury is a prospective randomized controlled trial<sup>113</sup>. However, in this study the AT-TRS (Achilles tendon total rupture score) was lower in the PRP group, indicating that PRP had a detrimental effect on the repair of acutely injured tendons. It should be noted that, in this study, all postoperative patients used a cast for 7 weeks, which could have prevented the mechanical stimulation of tendons that is necessary for tendon healing<sup>114</sup>. Moreover, an excessive concentration of platelets in PRP (17 times that in whole blood) might have been a factor that hindered tendon healing.

#### **Tendons with chronic injury**

In clinical sports medicine PRP is widely used for the treatment of chronic tendon injuries, particularly elbow-, Achilles-, and patellar-tendinopathy. However, the reported effects of PRP on these conditions vary among different studies. While clinical results have consistently shown the effectiveness of PRP in the treatment of chronic elbow tendinopathy<sup>115</sup>, studies on its efficacy in the treatment of chronic Achilles- and patellar-tendinopathy have reported conflicting results<sup>116-119</sup>.

#### **Elbow tendinopathy**

As mentioned above, PRP applications have been consistently effective in the treatment of elbow tendinopathy. In a number of RCT studies, PRP injec-

tions significantly improved outcome measure scores, including VAS (Visual Analog Scale, one of the most commonly used measures of pain intensity) and DASH (Disabilities of the Arm, Shoulder, and Hand) scores in the experimental groups compared to the control groups, which were injected with either whole blood, saline, or corticosteroid<sup>13,31,115,120-122</sup>. In one study that compared PRP with corticosteroid injection, the results showed significantly better VAS and DASH scores in the PRP group than in the corticosteroid group, which showed better scores initially followed by a decline, whereas the PRP group showed progressive improvement<sup>121</sup>.

### **Achilles tendinopathy**

In a prospective case series study where PRP was used to treat chronic Achilles tendinopathy, significant improvements were reported in clinical scores and ultrasonographic assessment<sup>116</sup>. In follow-up visits 18 months after treatment, AOFAS (American Orthopedic Foot and Ankle Society) scale scores (a scoring system to assess and monitor patients after foot and ankle surgery) improved from 55 to 96 points ( $P < 0.01$ ), while the VISA-A (Victorian Institute of Sport Assessment-Achilles) scale scores (a scoring system to assess patients with Achilles tendinopathy, with a score of 24 for very poor condition to a score of 90 for excellent condition) improved from 24 to 96 ( $P < 0.01$ ). Similar results were also reported 3 months after PRP treatment, with AOFAS scores increasing from 34 to 92<sup>117</sup>. In contrast, a growing number of studies showed no difference in function, pain, or healing tendon structure after PRP treatment<sup>118,119</sup>. In the stratified, block-randomized, double-blind, placebo-controlled trial study by de Vos et al.<sup>119</sup>, VISA-A scores improved in both the PRP injection group and the saline injection group, with no significant difference between the groups. Another Randomized Control Trial (RCT) in the same medical center reported similar results, with improved VISA-A scores and ultrasonographic tendon structures found in both PRP and control groups, without a significant difference between the groups<sup>118</sup>. One criticism of these two studies is that both the PRP and saline groups were given additional eccentric exercises, which may have overshadowed the possible beneficial effects of PRP<sup>123</sup>.

### **Patellar tendinopathy**

Studies on the treatment of human patellar tendinopathy with PRP have become more frequent only recently<sup>8,9,124-127</sup>. In a case series, PRP was injected three times every 15 days to treat patellar tendinopathy and patients showed significant improvements in Tegner activity scale (a score of activity level to assess patients with ligament injuries), VAS, and SF-36 scores (a score system to assess patients' physical and mental health, pain, social

function, etc.) at 6-month follow-up visits<sup>9</sup>. The same research group also conducted a prospective RCT and found similar results, with greater improvement in sport activity level in the PRP group (percentage improvement,  $39 \pm 22\%$ ) compared to the control group ( $20 \pm 27\%$ ) ( $P = 0.048$ )<sup>124</sup>.

### **Treatment of injured ligaments with PRP**

Clinical studies of PRP treatments for injured ligaments mainly focus on surgical anterior cruciate ligament (ACL) reconstruction, primarily because of the high incidence of ACL rupture in the United States which is 400,000 per annum<sup>51</sup>.

In a prospective, randomized, double-blind clinical trial<sup>128</sup>, contrast-enhanced magnetic resonance imaging (MRI) was used to evaluate the revascularization process in the osteo-ligamentous interface zone, which showed significantly higher vascularization in the PRP group ( $0.33 \pm 0.09$ ) compared to the control group ( $0.16 \pm 0.09$ ,  $P < 0.001$ ). The results from another RCT performed by the same group<sup>129</sup> reported improved knee stability after ACL reconstruction and local application of PRP. In contrast, an increasing number of studies have reported no benefits of PRP application. In these RCTs, no significant improvement was observed in graft MRIs, clinical or functional scores after PRP application<sup>109,130,131</sup>. The reason for the failure of PRP to confer any additional benefit over ACL reconstruction procedures was considered to be due to the presence of intra-articular plasmin in the post-traumatic joint<sup>51</sup>, which degrades fibrin within PRP, thus degrading it before it can exert its effect<sup>132</sup>.

### **Concluding remarks**

A large number of studies have demonstrated the beneficial effects of PRP on the healing of tendons and ligaments at the molecular, cellular, animal, and human trial levels, but the efficacy of PRP treatment for TLIs is still controversial in orthopaedics and sports medicine fields. This situation may be attributed to the complexity and diversity of PRP preparations used in these studies. Therefore, there is a pressing need to study the efficacy of PRP in the treatment of TLIs through basic science studies, especially given that clinical practices of PRP treatment are far ahead<sup>133,134</sup>. For this, several factors require optimization, including compositional variations in PRP preparations and the dosage used in treatments, among others. In addition, the same PRP treatment regimen, mainly in the form of PRP injections, is applied to all TLIs particularly tendinopathies. Because tendinopathy is a spectrum of tendon disorders<sup>135</sup>, the "one-size-fits-all" approach, generally consisting of PRP injections alone, may not be effective for all cases of tendinopathies, which can range from early stage, which is mainly inflammatory with damage to tendon matrices<sup>136</sup>, to advanced stage, which is mainly degenerative with extensive formation

of fatty tissues, cartilage-like tissues, and bone-like tissues (calcification), either alone or in combination, within tendon lesions<sup>137</sup>. Another layer of complexity is added by the age, gender, disease history, and treatment history of individuals in the studies. Lastly, subjective evaluation of PRP treatment effects, such as pain and functional scores from patients, cannot be completely avoided<sup>118,119</sup>. These limitations may be best addressed by studying outcomes of this treatment on well-defined animal models of tendinopathy. The healing process of TLIs is different from the healing of other tissues, and the biochemical and mechanical properties of healed tendons and ligaments never regain the properties of normal/uninjured tendons and ligaments due to scar formation after the repair of an injury. Therefore, the ultimate goals of TLI research should focus on using PRP to prevent scar formation, thus resulting in the recovery of normal structure and biomechanics of healed tendons and ligaments. In particular, some special characteristics of PRP should be taken into account. PRP contains a mixture of anabolic and catabolic mediators. These mediators may change, depending on the physiological and pathological states of the person and injury sites where PRP is delivered. It has been shown that tumor-conditioned platelets, which were derived from animals with highly-angiogenic tumors, exhibited enhanced neovascularization<sup>138</sup>. Additionally, some evidence suggests that the activated receptors in platelets may facilitate a selective release of growth factors<sup>139,140</sup>. Therefore, how to trigger the release of only beneficial cytokines from PRP may be an important direction for future research.

Complex relationships among various molecules may be studied via the neutralization of individual or multiple growth factors. Although there are some studies in this direction<sup>25,141</sup>, these relationships are still far from being clearly understood.

Moreover, when examining differing efficacies of PRP in TLI repairs, it should also be noted that tendons or ligaments at different sites vary in their potential for spontaneous healing. For example, ACLs are known to have poor healing potential compared to MCLs<sup>142,143</sup>. As a result, injury to ACLs often necessitates surgical intervention, whereas injured MCLs often require only conservative treatments in clinics.

Lastly, the effects of rehabilitation protocols after PRP treatment must also be established. Many controversies exist around these effects. Tendon healing in rats with post-operative mobilization was shown to be significantly better than the group that remained immobilized after operation<sup>114,144</sup>. Theoretically, mechanical stimulation should be given to patients once sufficient quantities of fibroblast and collagen are formed and are capable of transferring at least some of the mechanical load<sup>89</sup>. Although mechanical stimulation helps restore gliding function, enhances tendon/ligament strength and morphological restoration<sup>111,145-147</sup>, patients who undergo rupture repair operations are often immobilized in clinical conditions because of fear of re-rupture. Therefore, the need to provide appropriate and timely loading must be

weighed against the need to cast until fibroblasts and extracellular matrix have regenerated enough to bear the loading.

## Acknowledgements

We thank Dr. Nirmala Xavier for assistance in the preparation of this review. The funding for this work was provided by NIH under award numbers AR049921, AR060920, and AR061395 (JHW). The contents in this work do not necessarily reflect the views of NIH.

## References

1. James R, Kesturu G, Balian G, Chhabra AB. Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options. *J Hand Surg Am* 2008; 33:102-112.
2. Wang JH, Guo Q, Li B. Tendon biomechanics and mechanobiology—a minireview of basic concepts and recent advancements. *J Hand Ther* 2012; 25:133-140; quiz 141.
3. Khan U, Occleston NL, Khaw PT, McGrouther DA. Differences in proliferative rate and collagen lattice contraction between endotenon and synovial fibroblasts. *J Hand Surg Am* 1998; 23:266-273.
4. Evans RB. Managing the injured tendon: current concepts. *J Hand Ther* 2012; 25:173-189; quiz 190.
5. Longo UG, Lamberti A, Maffulli N, Denaro V. Tissue engineered biological augmentation for tendon healing: a systematic review. *Br Med Bull* 2011; 98:31-59.
6. Fenwick SA, Hazleman BL, Riley GP. The vasculature and its role in the damaged and healing tendon. *Arthritis Res* 2002; 4:252-260.
7. Finnoff JT, Fowler SP, Lai JK, Santrach PJ, Willis EA, et al. Treatment of chronic tendinopathy with ultrasound-guided needle tenotomy and platelet-rich plasma injection. *PM R* 2011; 3:900-911.
8. Brown J, Sivan M. Ultrasound-guided platelet-rich plasma injection for chronic patellar tendinopathy: a case report. *PM R* 2010; 2:969-972.
9. Kon E, Filardo G, Delcogliano M, Presti ML, Russo A, et al. Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. *Injury* 2009; 40:598-603.
10. Owens RF, Jr., Ginnetti J, Conti SF, Latona C. Clinical and magnetic resonance imaging outcomes following platelet rich plasma injection for chronic midsubstance Achilles tendinopathy. *Foot Ankle Int* 2011; 32:1032-1039.
11. Gosens T, Peerbooms JC, van Laar W, den Ouden BL. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. *Am J Sports Med* 2011; 39:1200-1208.
12. Scollon-Grieve KL, Malanga GA. Platelet-rich plasma injection for partial patellar tendon tear in a high school athlete: a case presentation. *PM R* 2011; 3:391-395.
13. Hechtman KS, Uribe JW, Botto-vanDemden A, Kiezbak GM. Platelet-rich plasma injection reduces pain in patients with recalcitrant epicondylitis. *Orthopedics* 2011; 34:92.
14. Yuan T, Guo SC, Han P, Zhang CQ, Zeng BF. Applications of leukocyte- and platelet-rich plasma (L-PRP) in trauma surgery. *Curr Pharm Biotechnol* 2012; 13:1173-1184.
15. Zhang J, Wang JH. Platelet-rich plasma releasate promotes differentiation of tendon stem cells into active tenocytes. *Am J Sports Med* 2010; 38:2477-2486.

16. Alsousou J, Ali A, Willett K, Harrison P. The role of platelet-rich plasma in tissue regeneration. *Platelets* 2013; 24:173-182.
17. Anitua E, Andia I, Sanchez M, Azofra J, del Mar Zaldueño M, et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. *J Orthop Res* 2005; 23:281-286.
18. Chen L, Dong SW, Tao X, Liu JP, Tang KL, et al. Autologous platelet-rich clot releasate stimulates proliferation and inhibits differentiation of adult rat tendon stem cells towards non-tenocyte lineages. *J Int Med Res* 2012; 40:1399-1409.
19. Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. *Clin J Sport Med* 2011; 21:344-352.
20. Parafioriti A, Armiraglio E, Del Bianco S, Tibalt E, Oliva F, et al. Single injection of platelet-rich plasma in a rat Achilles tendon tear model. *Muscles Ligaments Tendons J* 2011; 1:41-47.
21. Yoshikawa Y, Abrahamsson SO. Dose-related cellular effects of platelet-derived growth factor-BB differ in various types of rabbit tendons in vitro. *Acta Orthop Scand* 2001; 72:287-292.
22. Rickert M, Jung M, Adiyaman M, Richter W, Simank HG. A growth and differentiation factor-5 (GDF-5)-coated suture stimulates tendon healing in an Achilles tendon model in rats. *Growth Factors* 2001; 19:115-126.
23. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. *Sports Med* 2003; 33:381-394.
24. Kurtz CA, Loebig TG, Anderson DD, DeMeo PJ, Campbell PG. Insulin-like growth factor I accelerates functional recovery from Achilles tendon injury in a rat model. *Am J Sports Med* 1999; 27:363-369.
25. Chang J, Thunder R, Most D, Longaker MT, Lineaweaver WC. Studies in flexor tendon wound healing: neutralizing antibody to TGF-beta1 increases postoperative range of motion. *Plast Reconstr Surg* 2000; 105:148-155.
26. Xie X, Wang Y, Zhao C, Guo S, Liu S, et al. Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. *Biomaterials* 2012; 33:7008-7018.
27. Marx RE. Platelet-rich plasma: evidence to support its use. *J Oral Maxillofac Surg* 2004; 62:489-496.
28. de Mos M, van der Windt AE, Jahr H, van Schie HTM, Weinans H, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. *Am J Sports Med* 2008; 36:1171-1178.
29. Kajikawa Y, Morihara T, Sakamoto H, Matsuda K, Oshima Y, et al. Platelet-rich plasma enhances the initial mobilization of circulation-derived cells for tendon healing. *J Cell Physiol* 2008; 215:837-845.
30. Kampa RJ, Connell DA. Treatment of tendinopathy: is there a role for autologous whole blood and platelet rich plasma injection? *Int J Clin Pract* 2010; 64:1813-1823.
31. Mishra A, Woodall J, Jr., Vieira A. Treatment of tendon and muscle using platelet-rich plasma. *Clin Sports Med* 2009; 28:113-125.
32. Sanchez M, Anitua E, Azofra J, Andia I, Padilla S, et al. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. *Am J Sports Med* 2007; 35:245-251.
33. Dohan Ehrenfest DM, Bielecki T, Jimbo R, Barbe G, Del Corso M, et al. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). *Curr Pharm Biotechnol* 2012; 13:1145-1152.
34. Bielecki T, Dohan Ehrenfest DM, Everts PA, Wiczkowski A. The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives. *Curr Pharm Biotechnol* 2012; 13:1153-1162.
35. Anitua E, Sanchez M. We cannot take oranges for apples in the field of platelet-rich plasma products. *Scand J Med Sci Sports* 2012; 22:147-148.
36. Jenis LG, Banco RJ, Kwon B. A prospective study of Autologous Growth Factors (AGF) in lumbar interbody fusion. *Spine J* 2006; 6:14-20.
37. Everts PA, van Zundert A, Schonberger JP, Devilee RJ, Knape JT. What do we use: platelet-rich plasma or platelet-leukocyte gel? *J Biomed Mater Res A* 2008; 85:1135-1136.
38. Gardner MJ, Demetrakopoulos D, Klepchick PR, Mooar PA. The efficacy of autologous platelet gel in pain control and blood loss in total knee arthroplasty. An analysis of the haemoglobin, narcotic requirement and range of motion. *Int Orthop* 2007; 31:309-313.
39. Bielecki T, Gazdzik T, Arendt J, Szczepanski T, Król W, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances an in vitro study. *Journal of Bone & Joint Surgery, British Volume* 2007; 89:417-420.
40. Spang JT, Tischer T, Salzmann GM, Winkler T, Burgkart R, et al. Platelet concentrate vs. saline in a rat patellar tendon healing model. *Knee Surg Sports Traumatol Arthrosc* 2011; 19:495-502.
41. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? *Implant Dent* 2001; 10:225-228.
42. Mazzocca AD, McCarthy MB, Chowanec DM, Dugdale EM, Hansen D, et al. The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. *Am J Sports Med* 2012; 40:1742-1749.
43. Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, et al. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. *Clin Oral Implants Res* 2006; 17:212-219.
44. Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. *J Bone Joint Surg Br* 2009; 91:987-996.
45. Galliera E, Corsi MM, Banfi G. Platelet rich plasma therapy: inflammatory molecules involved in tissue healing. *J Biol Regul Homeost Agents* 2012; 26:35S-42S.
46. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leukocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol* 2009; 27:158-167.
47. Weibrich G, Kleis WK, Buch R, Hitzler WE, Hafner G. The Harvest Smart PRP system versus the Friident-Schutze platelet-rich plasma kit. *Clin Oral Implants Res* 2003; 14:233-239.
48. Weibrich G, Kleis WK. Curasan PRP kit vs. PCCS PRP system. Collection efficiency and platelet counts of two different methods for the preparation of platelet-rich plasma. *Clin Oral Implants Res* 2002; 13:437-443.
49. Rapp M, Svoboda D, Wessel LM, Kaiser MM. Elastic Stable Intramedullary Nailing (ESIN), Orthoss(R) and Gravitational Platelet Separation--System (GPS(R)): an effective method of treatment for pathologic fractures of bone cysts in children. *BMC Musculoskelet Disord* 2011; 12:45.
50. Everts PA, Hoffmann J, Weibrich G, Mahoney CB, Schonberger JP, et al. Differences in platelet growth factor release and leukocyte kinetics during autologous platelet gel formation. *Transfus Med* 2006; 16:363-368.
51. Yoshida R, Murray MM. Peripheral blood mononuclear cells enhance the anabolic effects of platelet-rich plasma on anterior cruciate ligament fibroblasts. *J Orthop Res* 2013; 31:29-34.

52. Andersen MB, Pingel J, Kjaer M, Langberg H. Interleukin-6: a growth factor stimulating collagen synthesis in human tendon. *J Appl Physiol* 2011; 110:1549-1554.
53. McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. *J Bone Joint Surg Am* 2012; 94:e1431-1438.
54. Anitua E, Sanchez M, Orive G. The importance of understanding what is platelet-rich growth factor (PRGF) and what is not. *J Shoulder Elbow Surg* 2011; 20:e23-24; author reply e24.
55. van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. *Ann N Y Acad Sci* 2001; 936:426-437.
56. Magarian EM, Vavken P, Murray MM. Human anterior cruciate ligament fibroblasts from immature patients have a stronger in vitro response to platelet concentrates than those from mature individuals. *Knee* 2011; 18:247-251.
57. Sciore P, Boykiw R, Hart DA. Semiquantitative reverse transcription-polymerase chain reaction analysis of mRNA for growth factors and growth factor receptors from normal and healing rabbit medial collateral ligament tissue. *J Orthop Res* 1998; 16:429-437.
58. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nussgens BV, Lapiere CM. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. *Cancer Res* 1997; 57:5590-5597.
59. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, et al. Platelet-rich plasma: Growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1998; 85:638-646.
60. Lynch SE, Colvin RB, Antoniadis HN. Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. *J Clin Invest* 1989; 84:640-646.
61. Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, et al. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. *J Cell Biol* 1989; 109:429-440.
62. Letson AK, Dahners LE. The effect of combinations of growth factors on ligament healing. *Clin Orthop Relat Res* 1994:207-212.
63. Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. *Am J Surg* 1993; 165:728-737.
64. Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. *J Rheumatol* 1997; 24:1253-1259.
65. Petersen W, Unterhauser F, Pufe T, Zantop T, Sudkamp NP, et al. The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed during the remodeling of free tendon grafts in sheep. *Arch Orthop Trauma Surg* 2003; 123:168-174.
66. Wei XL, Lin L, Hou Y, Fu X, Zhang JY, et al. Construction of recombinant adenovirus co-expression vector carrying the human transforming growth factor-beta1 and vascular endothelial growth factor genes and its effect on anterior cruciate ligament fibroblasts. *Chin Med J (Engl)* 2008; 121:1426-1432.
67. Zhang F, Liu H, Stile F, Lei MP, Pang Y, et al. Effect of vascular endothelial growth factor on rat Achilles tendon healing. *Plast Reconstr Surg* 2003; 112:1613-1619.
68. Tohyama H, Yoshikawa T, Ju YJ, Yasuda K. Revascularization in the tendon graft following anterior cruciate ligament reconstruction of the knee: its mechanisms and regulation. *Chang Gung Med J* 2009; 32:133-139.
69. Yoshikawa T, Tohyama H, Katsura T, Kondo E, Kotani Y, et al. Effects of local administration of vascular endothelial growth factor on mechanical characteristics of the semitendinosus tendon graft after anterior cruciate ligament reconstruction in sheep. *Am J Sports Med* 2006; 34:1918-1925.
70. DesRosiers EA, Yahia L, Rivard CH. Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors. *J Orthop Res* 1996; 14:200-208.
71. Gillery P, Leperre A, Maquart FX, Borel JP. Insulin-like growth factor-I (IGF-I) stimulates protein synthesis and collagen gene expression in monolayer and lattice cultures of fibroblasts. *J Cell Physiol* 1992; 152:389-396.
72. Hansen M, Boesen A, Holm L, Flyvbjerg A, Langberg H, et al. Local administration of insulin-like growth factor-I (IGF-I) stimulates tendon collagen synthesis in humans. *Scand J Med Sci Sports* 2012:doi: 10.1111/j.1600-0838.2011.01431.x.
73. Lyras DN, Kazakos K, Verettas D, Chronopoulos E, Folaranmi S, et al. Effect of combined administration of transforming growth factor-b1 and insulin-like growth factor I on the mechanical properties of a patellar tendon defect model in rabbits. *Acta Orthop Belg* 2010; 76:380-386.
74. Throm AM, Liu WC, Lock CH, Billiar KL. Development of a cell-derived matrix: effects of epidermal growth factor in chemically defined culture. *J Biomed Mater Res A* 2010; 92:533-541.
75. Marui T, Niyibizi C, Georgescu HI, Cao M, Kavalkovich KW, et al. Effect of growth factors on matrix synthesis by ligament fibroblasts. *J Orthop Res* 1997; 15:18-23.
76. Hagerty P, Lee A, Calve S, Lee CA, Vidal M, et al. The effect of growth factors on both collagen synthesis and tensile strength of engineered human ligaments. *Biomaterials* 2012; 33:6355-6361.
77. Wasterlain AS, Braun HJ, Harris AH, Kim HJ, Dragoo JL. The systemic effects of platelet-rich plasma injection. *Am J Sports Med* 2013; 41:186-193.
78. Chan BP, Chan KM, Maffulli N, Webb S, Lee KK. Effect of basic fibroblast growth factor. An in vitro study of tendon healing. *Clin Orthop Relat Res* 1997:239-247.
79. Folkman J, Klagsbrun M. Angiogenic factors. *Science* 1987; 235:442-447.
80. Mansukhani A, Dell'Era P, Moscatelli D, Kornbluth S, Hanafusa H, et al. Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. *Proc Natl Acad Sci U S A* 1992; 89:3305-3309.
81. Zhang J, Middleton KK, Fu FH, Im HJ, JH W. HGF Mediates the Anti-inflammatory Effects of PRP on Injured Tendons. *PlosOne* 2013; 8:e67303.
82. Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: the state of play. *Br J Sports Med* 2008; 42:314-320.
83. Van Belle E, Witzenchler B, Chen D, Silver M, Chang L, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. *Circulation* 1998; 97:381-390.
84. Ueshima K, Kitaoka K, Nakase J, Xu Q, Matsumoto K, et al. Promotion of rabbit ligament healing by local delivery of hepatocyte growth factor. *J Orthop Sci* 2011; 16:451-457.
85. Nakase J, Kitaoka K, Matsumoto K, Tomita K. Facilitated tendon-bone healing by local delivery of recombinant hepatocyte growth factor in rabbits. *Arthroscopy* 2010; 26:84-90.
86. Ono I, Yamashita T, Hida T, Jin HY, Ito Y, et al. Local administration of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. *J Surg Res* 2004; 120:47-55.
87. Franco D, Franco T, Schettino AM, Filho JM, Vendramin FS. Protocol for Obtaining Platelet-Rich Plasma (PRP), Platelet-Poor Plasma (PPP), and Thrombin for Autologous Use. *Aesthetic Plast Surg* 2012; 36:1254-1259.

88. Landesberg R, Moses M, Karpatkin M. Risks of using platelet rich plasma gel. *J Oral Maxillofac Surg* 1998; 56:1116-1117.
89. Virchenko O, Grenegard M, Aspenberg P. Independent and additive stimulation of tendon repair by thrombin and platelets. *Acta Orthop* 2006; 77:960-966.
90. Coughlin SR. Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo. *Arterioscler Thromb Vasc Biol* 1998; 18:514-518.
91. Moojen DJ, Everts PA, Schure RM, Overdeest EP, van Zundert A, et al. Antimicrobial activity of platelet-leukocyte gel against *Staphylococcus aureus*. *J Orthop Res* 2008; 26:404-410.
92. Jia WT, Zhang CQ, Wang JQ, Feng Y, Ai ZS. The prophylactic effects of platelet-leucocyte gel in osteomyelitis: an experimental study in a rabbit model. *J Bone Joint Surg Br* 2010; 92:304-310.
93. Li H, Hamza T, Tidwell JE, Clovis N, Li B. Unique Antimicrobial Effects of Platelet-Rich Plasma and Its Efficacy as a Prophylaxis to Prevent Implant-Associated Spinal Infection. *Adv Healthc Mater* 2013;doi: 10.1002/adhm.201200465.
94. Drago L, Bortolin M, Vassena C, Taschieri S, Del Fabbro M. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. *BMC Microbiol* 2013; 13:47.
95. Berthet J, Damien P, Hamzeh-Cognasse H, Arthaud CA, Eyraud MA, et al. Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. *Clinical Immunology* 2012; 145:189-200.
96. Aspenberg P, Virchenko O. Platelet concentrate injection improves Achilles tendon repair in rats. *Acta Orthop Scand* 2004; 75:93-99.
97. Lyras D, Kazakos K, Verettas D, Polychronidis A, Simopoulos C, et al. Immunohistochemical study of angiogenesis after local administration of platelet-rich plasma in a patellar tendon defect. *Int Orthop* 2010; 34:143-148.
98. Lyras DN, Kazakos K, Verettas D, Botaitis S, Agrogiannis G, et al. The effect of platelet-rich plasma gel in the early phase of patellar tendon healing. *Arch Orthop Trauma Surg* 2009; 129:1577-1582.
99. Murray MM, Spindler KP, Ballard P, Welch TP, Zurakowski D, et al. Enhanced histologic repair in a central wound in the anterior cruciate ligament with a collagen-platelet-rich plasma scaffold. *J Orthop Res* 2007; 25:1007-1017.
100. Anitua E, Sanchez M, Nurden AT, Zalduendo M, de la Fuente M, et al. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. *J Biomed Mater Res A* 2006; 77:285-293.
101. McCarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. *J Orthop Res* 2009; 27:1033-1042.
102. Kaux JF, Drion PV, Colige A, Pascon F, Libertiaux V, et al. Effects of platelet-rich plasma (PRP) on the healing of Achilles tendons of rats. *Wound Repair Regen* 2012; 20:748-756.
103. Bi Y, Ehrirchiou D, Kilts TM, Inkson CA, Embree MC, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. *Nat Med* 2007; 13:1219-1227.
104. Rui YF, Lui PP, Li G, Fu SC, Lee YW, et al. Isolation and Characterization of Multipotent Rat Tendon-Derived Stem Cells. *Tissue Eng Part A* 2010; 16:1549-1558.
105. Bertrand-Duchesne MP, Grenier D, Gagnon G. Epidermal growth factor released from platelet-rich plasma promotes endothelial cell proliferation in vitro. *J Periodontal Res* 2010; 45:87-93.
106. Matsui M, Tabata Y. Enhanced angiogenesis by multiple release of platelet-rich plasma contents and basic fibroblast growth factor from gelatin hydrogels. *Acta Biomater* 2012; 8:1792-1801.
107. Davidson CJ, Ganion LR, Gehlsen GM, Verhoestra B, Roepke JE, et al. Rat tendon morphologic and functional changes resulting from soft tissue mobilization. *Med Sci Sports Exerc* 1997; 29:313-319.
108. Caplan AL. Bone development and repair. *Bioessays* 1987; 6:171-175.
109. Ventura A, Terzaghi C, Borgo E, Verdoia C, Gallazzi M, et al. Use of growth factors in ACL surgery: preliminary study. *Journal of Orthopaedics and Traumatology* 2005; 6:76-79.
110. Paoloni J, De Vos RJ, Hamilton B, Murrell GA, Orchard J. Platelet-rich plasma treatment for ligament and tendon injuries. *Clin J Sport Med* 2011; 21:37-45.
111. Kannus P, Jozsa L, Natri A, Jarvinen M. Effects of training, immobilization and remobilization on tendons. *Scand J Med Sci Sports* 1997; 7:67-71.
112. Pajala A, Kangas J, Ohtonen P, Leppilahti J. Rupture and deep infection following treatment of total Achilles tendon rupture. *J Bone Joint Surg Am* 2002; 84-A:2016-2021.
113. Schepull T, Kvist J, Norrman H, Trinks M, Berlin G, et al. Autologous platelets have no effect on the healing of human achilles tendon ruptures: a randomized single-blind study. *Am J Sports Med* 2011; 39:38-47.
114. Virchenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechanical stimulation. *Acta Orthop* 2006; 77:806-812.
115. Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. *Am J Sports Med* 2011; 39:2130-2134.
116. Gaweda K, Tarczynska M, Krzyzanowski W. Treatment of Achilles tendinopathy with platelet-rich plasma. *Int J Sports Med* 2010; 31:577-583.
117. Monto RR. Platelet rich plasma treatment for chronic Achilles tendinosis. *Foot Ankle Int* 2012; 33:379-385.
118. de Jonge S, de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. *Am J Sports Med* 2011; 39:1623-1629.
119. de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. *JAMA* 2010; 303:144-149.
120. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. *The American journal of sports medicine* 2006; 34:1774-1778.
121. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. *Am J Sports Med* 2010; 38:255-262.
122. Rabago D BT, Zgierska AE, Zeisig E, Ryan M, et al. A systematic review of four injection therapies for lateral epicondylitis: prolotherapy, polidocanol, whole blood and platelet-rich plasma. *Br J Sports Med* 2009; 43:471-481.
123. Creaney L. Platelet-rich plasma for treatment of Achilles tendinopathy. *JAMA* 2010; 303:1696; author reply 1697-1698.
124. Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, et al. Use of platelet-rich plasma for the treatment of refractory jumper's knee. *Int Orthop* 2010; 34:909-915.
125. Mautner K, Colberg RE, Malanga G, Borg-Stein JP, Harmon KG, et al. Outcomes after ultrasound-guided platelet-rich plasma injections for chronic tendinopathy: a multicenter, retrospective review. *PM R* 2013; 5:169-175.

126. Harmon K, Drezner J, Rao A. Platelet rich plasma for chronic tendinopathy. *Br J Sports Med* 2013; 47:x-e2.
127. Ferreroa G, Fabbro E, Orlandia D, Martinia C, Lacellib F, et al. Ultrasound-guided injection of platelet-rich plasma in chronic Achilles and patellar tendinopathy. *J Ultrasound* 2012; 15:260-266.
128. Vogrin M, Ruprecht M, Dinevski D, Haspl M, Kuhta M, et al. Effects of a platelet gel on early graft revascularization after anterior cruciate ligament reconstruction: a prospective, randomized, double-blind, clinical trial. *Eur Surg Res* 2010; 45:77-85.
129. Vogrin M, Ruprecht M, Crnjac A, Dinevski D, Krajnc Z, et al. The effect of platelet-derived growth factors on knee stability after anterior cruciate ligament reconstruction: a prospective randomized clinical study. *Wien Klin Wochenschr* 2010; 122 Suppl 2:91-95.
130. Silva A, Sampaio R. Anatomic ACL reconstruction: does the platelet-rich plasma accelerate tendon healing? *Knee Surg Sports Traumatol Arthrosc* 2009; 17:676-682.
131. Nin JR, Gasque GM, Azcarate AV, Beola JD, Gonzalez MH. Has platelet-rich plasma any role in anterior cruciate ligament allograft healing? *Arthroscopy* 2009; 25:1206-1213.
132. Harrold AJ. The defect of blood coagulation in joints. *J Clin Pathol* 1961; 14:305-308.
133. Engebretsen L, Steffen K, Alsousou J, Anitua E, Bachl N, et al. IOC consensus paper on the use of platelet-rich plasma in sports medicine. *Br J Sports Med* 2010; 44:1072-1081.
134. Del Buono A, Papalia R, Denaro V, Maccauro G, Maffulli N. Platelet rich plasma and tendinopathy: state of the art. *Int J Immunopathol Pharmacol* 2011; 24:79-83.
135. Jiang D, Wang JH. Tendinopathy and its treatment with platelet-rich plasma (PRP). *Histol Histopathol* 2013; Epub date June 16.
136. Nakama LH, King KB, Abrahamsson S, Rempel DM. Evidence of tendon microtears due to cyclical loading in an in vivo tendinopathy model. *J Orthop Res* 2005; 23:1199-1205.
137. Kannus P, Jozsa L. Histopathological changes preceding spontaneous rupture of a tendon. A controlled study of 891 patients. *J Bone Joint Surg Am* 1991; 73:1507-1525.
138. Pietramaggiore G, Scherer SS, Cervi D, Klement G, Orgill DP. Tumors stimulate platelet delivery of angiogenic factors in vivo: an unexpected benefit. *Am J Pathol* 2008; 173:1609-1616.
139. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. *Blood* 2008; 111:1227-1233.
140. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. *Blood* 2008; 111:1201-1207.
141. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. *J Cell Sci* 1994; 107 ( Pt 5):1137-1157.
142. Nagineni CN, Amiel D, Green MH, Berchuck M, Akeson WH. Characterization of the intrinsic properties of the anterior cruciate and medial collateral ligament cells: an in vitro cell culture study. *J Orthop Res* 1992; 10:465-475.
143. Hannafin JA, Attia ET, Warren RF, Bhargava MM. Characterization of chemotactic migration and growth kinetics of canine knee ligament fibroblasts. *J Orthop Res* 1999; 17:398-404.
144. Eliasson P, Andersson T, Aspenberg P. Rat Achilles tendon healing: mechanical loading and gene expression. *J Appl Physiol* 2009; 107:399-407.
145. Maffulli N, King JB. Effects of physical activity on some components of the skeletal system. *Sports Med* 1992; 13:393-407.
146. Zeichen J, van Griensven M, Bosch U. The proliferative response of isolated human tendon fibroblasts to cyclic biaxial mechanical strain. *Am J Sports Med* 2000; 28:888-892.
147. Voleti PB, Buckley MR, Soslowky LJ. Tendon healing: repair and regeneration. *Annu Rev Biomed Eng* 2012; 14:47-71.